Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PET

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
ROC curve for percent change in average SUVs.

TABLE 1

Single- and Dual-Time-Point Imaging SUVs in Patients with Malignant Lesions

Sample	Average SUV at time:			% Change in average SUV	Histopathologic findings	Tumor grade	Size (cm)
Sample		1	2	% Change in average SUV	Histopathologic findings	Tumor grade	Size (cm)
1	1.2	1.4	16.7	IDC	Low	0.2
2	1.5	1.7	13.3	IDC	High	1.5
3	0.7	0.7	0	IDC + ILC	Moderate	3.5
4	0.6	0.7	16.7	IDC	Not known	1.0
5	1.1	0.9	−18.2	IDC	Moderate	0.2
6	3.0	3.3	10.0	IDC	High	2.0
7	2.1	2.3	9.5	IDC	Moderate	2.4
8	2.1	2.2	4.8	IDC + ILC	Low	4.0
9	1.4	1.6	14.3	IDC	Moderate	0.5
10	1.9	2.3	21.1	IDC	High	Not known
11	1.8	1.9	5.6	ILC + IDC	Moderate	1.5
12	0.8	0.9	12.5	IDC	Low	Not known
13	7.4	9.1	23.0	IDC	High	Not known
14	2.3	2.5	8.7	IDC	Moderate	2.9
15	1.8	2.0	11.1	IDC	Moderate	1.9
16	0.9	0.9	0	IDC	Moderate	1.6
17	2.0	2.3	15.0	IDC	Low	3.5
18	2.7	3.5	29.6	IDC + ILC	High	2.4
19	0.6	0.8	33.3	IDC	Low	1.6
20	11.7	15.7	34.2	IDC	High	2.6
21	0.7	0.8	14.3	IDC	Low	1.4
22	2.9	3.2	10.3	IDC	Moderate	2.1
23	15.3	20.0	30.7	IDC	High	2.8
24	5.7	5.9	3.5	IDC	High	1.9
25	0.7	0.7	0	IDC + ILC	Low	0.3
26	6.0	6.9	15.0	Medullary carcinoma	High	1.8
27	5.2	5.8	11.5	IDC	Moderate	2.5
28	2.2	2.4	9.1	IDC	High	2.2
29	1.5	1.7	13.3	IDC	Moderate	1.2
30	0.4	0.4	0	IDC	Moderate	0.4
31	2.5	2.6	4.0	IDC	High	0.5
32	2.5	2.7	8.0	IDC	Low	Not known
33	1.7	1.9	11.8	IDC + ILC	Low	Not known
34	1.4	1.7	21.4	IDC	Moderate	0.9
35	0.8	1.0	25	IDC	High	Not known
36	2.7	3.6	33.3	IDC	Moderate	1.0
37	6.2	7.7	24.2	IDC	Moderate	4.0
38	3.0	3.2	6.7	IDC	Moderate	Not known
39	3.3	3.0	−9.1	Adenocarcinoma	Not known	Not known
Mean	2.88	3.38	12.7
SD	3.04	3.98	11.4

TABLE 2

Single- and Dual-Time-Point Imaging SUVs in Patients with Postbiopsy Inflammation

Sample	Average SUV at time:			% Change in average SUV	Histopathologic findings
Sample		1	2	% Change in average SUV	Histopathologic findings
1	1.7	1.4	−0.176	No tumor, Bx Rx +
2	1.1	0.8	−0.273	Benign, Bx Rx +
3	1.5	1.9	0.267	No tumor, Bx Rx +, Ch Inf
4	1.3	1.1	−0.154	No tumor, Bx Rx +
5	1.0	0.7	−0.300	No tumor
6	1.3	1.2	−0.077	No tumor, Bx Rx +
7	1.0	0.8	−0.200	No tumor, Bx Rx +
8	1.0	1.1	0.100	Bx Rx +, proliferative fibroblasts
9	1.6	1.6	0	No tumor, Bx Rx +
10	1.5	1.3	−0.133	No tumor, Bx Rx +
11	1.0	0.8	−0.200	No tumor, Bx Rx +
12	0.8	0.6	−0.250	No tumor, Bx Rx +
13	1.4	1.3	−0.071	No tumor, Bx Rx +
14	1.5	1.4	−0.067	Benign, Bx Rx +
15	2.0	1.9	−0.050	No tumor, Bx Rx +
16	1.5	1.5	0	No tumor, Bx Rx +
17	1.5	1.7	0.133	Bx Rx, foreign-body giant-cell reaction
18	0.5	0.3	−0.400	No tumor, Bx Rx +
Mean	1.29	1.19	−0.103
SD	0.36	0.45	0.166